[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100482374":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":30,"responsibleParty":53,"collaborators":25,"id":55,"slug":25,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":25,"maxAge":25,"enrollmentInfo":63,"targetDuration":25,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":77,"overallStatus":32,"whyStopped":25,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Sunnybrook Health Sciences Centre","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"rTMS + methylphenidate","EXPERIMENTAL","repetitive transcranial magnetic stimulation (rTMS) and methylphenidate",[13,14],"Device: rTMS","Drug: methylphenidate",{"label":16,"type":10,"description":17,"interventionNames":18},"rTMS only","repetitive transcranial magnetic stimulation (rTMS) only",[13],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","rTMS","repetitive transcranial magnetic stimulation",[9,16],null,{"type":27,"name":28,"description":28,"armGroupLabels":29,"otherNames":25},"DRUG","methylphenidate",[9],[31],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Toronto","Ontario","M4N 3M5","Canada",{"type":38,"coordinates":39},"Point",[40,41],-79.39864,43.70643,{"lat":41,"lon":40},[44,50],{"name":45,"role":46,"phone":47,"phoneExt":48,"email":49},"Carla Zucchero-Sarracini","CONTACT","416-480-6100","63185","memoryresearch@sunnybrook.ca",{"name":51,"role":52,"phone":25,"phoneExt":25,"email":25},"Krista L Lanctôt, PhD","PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100482374",false,"NCT05561205","rTMS for Apathy Clinical Trial","Repetitive Transcranial Magnetic Stimulation for Apathy Clinical Trial (REACT)","REACT","Inclusion Criteria:\n\n* mild or major neurocognitive disorder OR mild behavioural impairment\n* Apathy for at least 4 weeks\n* Stable dose of medication (\\>4 weeks) that may affect cognition or behaviour\n* Care partner who spends at least 10 hours a week with the subject\n\nExclusion Criteria:\n\n* Current major depressive episode\n* Agitation, delusions, hallucination\n* Medical contraindications to rTMS\n* Currently taking an amphetamine product\n* Central nervous system abnormalities, Tourette's syndrome, or motor tics\n* Current participation in another clinical trial","ALL",{"count":64,"type":65},10,"ESTIMATED","INTERVENTIONAL",[68],"NA","Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiving methylphenidate and individuals not receiving medication for apathy.",[71,72,73,74,75,76],"Alzheimer Disease","Apathy in Dementia","Dementia","Mild Behavioural Impairment","Mild Cognitive Impairment","Neurocognitive Disorders",[78,79,80,81],"Apathy","Alzheimer's disease","Neurocognitive disorder","Mild behavioural impairment","2026-04-10",{"date":84,"type":85},"2026-04-13","ACTUAL",{"date":87,"type":85},"2023-02-09",{"date":89,"type":65},"2026-12-01",{"name":5,"class":6},1]